Phenotype-driven management of diabetic macular edema: multimodal imaging biomarkers and individualized therapy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Individualized Treatment Approaches for Diabetic Macular Edema: Utilizing Multimodal Imaging Biomarkers for Phenotype-Based Management

  • By

  • Zichao You

  • Li Jiang

  • Ying-rui Liu

  • Ming Ming Yang

  • June 23, 2026

Share

  • 1

    Diabetic macular edema (DME) is a leading cause of visual impairment in adults with diabetes mellitus.

  • 2

    Intravitreal anti-VEGF therapies are the first-line treatment for DME, but 30-50% of patients show inadequate responses.

  • 3

    Multimodal imaging techniques like OCT, OCTA, and UWF-FA help identify structural and microvascular changes in DME.

  • 4

    The review categorizes imaging biomarkers into disease activity markers and predictors of visual prognosis.

  • 5

    DME can be classified into five clinical phenotypes based on distinct biomarker profiles for tailored treatment.

Original Source(s)

Phenotype-driven management of diabetic macular edema: multimodal imaging biomarkers and individualized therapy

  • by Zichao You, Li Jiang, Ying-rui Liu, Ming Ming Yang

  • June 23, 2026

Related Content

Levels of vascular endothelial growth factor and filtration surgery outcomes in diabetic patients with acute primary angle closure

Retinal Age Model Tied to Disease Risk

Fundus-based tool estimates biologic aging but shows modest gains over prior models

GLP-1 RAs Associated With Small ION Risk Increase

In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.